Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK.
Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv26-31. doi: 10.1093/rheumatology/ker243.
The Sheffield RA health economic model has been used in several published cost-effectiveness analyses in both the UK and internationally to evaluate different treatments for patients with RA. This article presents the key methods and assumptions that underpin the model, including justifications for using an individual patient sampling methodology, and why the model has used the HAQ to track disease activity. The article also details how trial and observational data are used in the model to address specific questions. The model has been used to support health policy in both the UK and internationally, although the limited evidence still provides a challenge when using an economic model to determine the cost-effectiveness of RA treatments. The results of analyses using the Sheffield RA model are presented. The limitations of the model are discussed, and improvements are continually required to provide a model that is appropriate to address health economic questions in the future. The Sheffield RA model continues to be used and refined, and allows health economic questions to be answered using a transparent and flexible modelling methodology.
谢菲尔德 RA 健康经济模型已在英国和国际上的几项已发表的成本效益分析中使用，以评估不同的 RA 患者治疗方法。本文介绍了支撑该模型的关键方法和假设，包括使用个体患者抽样方法的理由，以及为什么该模型使用 HAQ 来跟踪疾病活动。本文还详细介绍了如何在模型中使用试验和观察数据来解决具体问题。该模型已在英国和国际上用于支持卫生政策，尽管有限的证据在使用经济模型来确定 RA 治疗的成本效益时仍然构成挑战。本文介绍了使用谢菲尔德 RA 模型进行的分析结果。讨论了模型的局限性，并需要不断改进，以提供一种适合未来解决卫生经济问题的模型。谢菲尔德 RA 模型仍在使用和完善，并允许使用透明和灵活的建模方法来回答卫生经济问题。
